Dyne, Avidity initiated at outperform by RBC on DM1 drugs

seekingalpha

2024-11-27

Hailshadow/iStock via Getty Images

RBC Capital has initiated coverage of Dyne Therapeutics (NASDAQ:DYN) and Avidity Biosciences (NASDAQ:RNA) with outperform ratings, commenting that the two companies may have “cracked the code” for muscle with their respective drug platforms.

RBC noted that while Avidity (RNA) is

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2486836058"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486836058\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2486836058?lang=zh_CN&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1043991730/image_1043991730.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-11-27 02:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486836058","market":"fut","top_or_hot":-1,"title":"Dyne, Avidity initiated at outperform by RBC on DM1 drugs","media":"seekingalpha","content":"<html><body><figure> <picture> <img height=\"1024px\" sizes=\"(max-width: 768px) calc(100vw - 36px), (max-width: 1024px) calc(100vw - 132px), (max-width: 1200px) calc(66.6vw - 72px), 600px\" src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1043991730/image_1043991730.jpg?io=getty-c-w750\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1043991730/image_1043991730.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1043991730/image_1043991730.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1043991730/image_1043991730.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1043991730/image_1043991730.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1043991730/image_1043991730.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1043991730/image_1043991730.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1043991730/image_1043991730.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1043991730/image_1043991730.jpg?io=getty-c-w240 240w\" width=\"1536px\"/> </picture> <figcaption><p>Hailshadow/iStock via Getty Images</p></figcaption> </figure><p>RBC Capital has initiated coverage of Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (<span>NASDAQ:DYN</span>) and Avidity Biosciences (<span>NASDAQ:RNA</span>) with outperform ratings, commenting that the two companies may have “cracked the code” for muscle with their respective drug platforms.</p> <div></div><p>RBC noted that while Avidity (RNA) is</p></body></html>","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dyne, Avidity initiated at outperform by RBC on DM1 drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDyne, Avidity initiated at outperform by RBC on DM1 drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-27 02:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4336451-dyne-avidity-initiated-at-outperform-by-rbc-on-dm1-drugs><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hailshadow/iStock via Getty Images RBC Capital has initiated coverage of Dyne Therapeutics (NASDAQ:DYN) and Avidity Biosciences (NASDAQ:RNA) with outperform ratings, commenting that the two companies ...</p>\n\n<a href=\"https://seekingalpha.com/news/4336451-dyne-avidity-initiated-at-outperform-by-rbc-on-dm1-drugs\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DYN","symbol_name":"戴纳基","start_time":0,"source_url":"https://seekingalpha.com/news/4336451-dyne-avidity-initiated-at-outperform-by-rbc-on-dm1-drugs","article_id":"2486836058","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1043991730/image_1043991730.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486836058","pubTimestamp":1732644183,"columns":[],"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Hailshadow/iStock via Getty Images RBC Capital has initiated coverage of Dyne Therapeutics  and Avidity Biosciences  with outperform ratings, commenting that the two companies may have “cracked the code” for muscle with their respective drug platforms. RBC noted that while Avidity  is","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"DYN":"戴纳基","RNA":"Avidity Biosciences, Inc."},"translate_title":"Dyne，RBC对DM1药物发起的亲和力跑赢大盘","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DYN":0.9,"RNA":0.9},"content_text":"Hailshadow/iStock via Getty Images RBC Capital has initiated coverage of Dyne Therapeutics (NASDAQ:DYN) and Avidity Biosciences (NASDAQ:RNA) with outperform ratings, commenting that the two companies may have “cracked the code” for muscle with their respective drug platforms. RBC noted that while Avidity (RNA) is","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}